The Destiny Group

Destiny Pharma is a clinical-stage biotechnology company dedicated to the development of novel anti-infectives designed to address the global threat of antimicrobial resistance. The company's lead asset, XF-73 (exeporfinium chloride), is a first-in-class synthetic dicationic porphyrin nasal gel that has completed Phase 2b trials for the prevention of post-surgical staphylococcal infections. Its second major program, NTCD-M3, is a microbiome-based biotherapeutic ready for Phase 3 trials to prevent the recurrence of Clostridioides difficile infection. The company's proprietary XF platform utilizes a unique mechanism of action that rapidly de-energizes bacterial cells, significantly reducing the likelihood of resistance development. Following financial challenges in 2024, the company entered administration and its core assets were acquired by EMV Capital in 2025 to continue their clinical advancement.